S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Bellerophon Therapeutics Stock Forecast, Price & News

-0.19 (-6.69%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
42,625 shs
Average Volume
39,353 shs
Market Capitalization
$25.20 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive BLPH News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellerophon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Bellerophon Therapeutics logo

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc. focuses on developing products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Its product pipeline include PH-ILD, PH-COPD and PH-Sarc. The company was founded in 2009 and is headquartered in Warren, NJ.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$2.71 per share


Net Income
$-24.73 million
Pretax Margin




Free Float
Market Cap
$25.20 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.44 out of 5 stars

Medical Sector

1096th out of 1,390 stocks

Pharmaceutical Preparations Industry

518th out of 668 stocks

Analyst Opinion: 0.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Bellerophon Therapeutics (NASDAQ:BLPH) Frequently Asked Questions

Is Bellerophon Therapeutics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Bellerophon Therapeutics stock.
View analyst ratings for Bellerophon Therapeutics
or view top-rated stocks.

How has Bellerophon Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Bellerophon Therapeutics' stock was trading at $6.29 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BLPH stock has decreased by 57.9% and is now trading at $2.65.
View which stocks have been most impacted by COVID-19

When is Bellerophon Therapeutics' next earnings date?

Bellerophon Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Bellerophon Therapeutics

How were Bellerophon Therapeutics' earnings last quarter?

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) posted its quarterly earnings results on Monday, November, 15th. The biotechnology company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.14.
View Bellerophon Therapeutics' earnings history

When did Bellerophon Therapeutics' stock split? How did Bellerophon Therapeutics' stock split work?

Bellerophon Therapeutics shares reverse split on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2020. An investor that had 100 shares of Bellerophon Therapeutics stock prior to the reverse split would have 7 shares after the split.

Who are Bellerophon Therapeutics' key executives?

Bellerophon Therapeutics' management team includes the following people:
  • Peter Fernandes, Chief Executive, Regulatory & Safety Officer
  • Parag Suresh Shah, Vice President-Business Operations
  • Nicholas Laccona, Chief Financial & Accounting Officer
  • Edwin L. Parsley, Chief Medical Officer
  • Martin Dekker, Vice President-Engineering & Manufacturing

What other stocks do shareholders of Bellerophon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Pfizer (PFE), Verastem (VSTM), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX) and Dynavax Technologies (DVAX).

When did Bellerophon Therapeutics IPO?

(BLPH) raised $60 million in an IPO on Friday, February 13th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

What is Bellerophon Therapeutics' stock symbol?

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

Who are Bellerophon Therapeutics' major shareholders?

Bellerophon Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.12%), BlackRock Inc. (1.27%) and Telemetry Investments L.L.C. (0.90%). Company insiders that own Bellerophon Therapeutics stock include New Mountain Investments Ii, L and Wassim Fares.
View institutional ownership trends for Bellerophon Therapeutics

Which institutional investors are selling Bellerophon Therapeutics stock?

BLPH stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Telemetry Investments L.L.C..
View insider buying and selling activity for Bellerophon Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Bellerophon Therapeutics stock?

BLPH stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc..
View insider buying and selling activity for Bellerophon Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Bellerophon Therapeutics?

Shares of BLPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bellerophon Therapeutics' stock price today?

One share of BLPH stock can currently be purchased for approximately $2.65.

How much money does Bellerophon Therapeutics make?

Bellerophon Therapeutics has a market capitalization of $25.20 million. The biotechnology company earns $-24.73 million in net income (profit) each year or ($2.27) on an earnings per share basis.

How many employees does Bellerophon Therapeutics have?

Bellerophon Therapeutics employs 21 workers across the globe.

What is Bellerophon Therapeutics' official website?

The official website for Bellerophon Therapeutics is www.bellerophon.com.

Where are Bellerophon Therapeutics' headquarters?

Bellerophon Therapeutics is headquartered at 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059.

How can I contact Bellerophon Therapeutics?

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company can be reached via phone at (908) 574-4770 or via email at [email protected].

This page was last updated on 12/4/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.